9k slot casino
2025-01-10   

West Virginia knocks off No. 3 Gonzaga 86-78 in overtime in the Battle 4 Atlantis9k slot casino 。

Wesco International EVP Christine Wolf sells stock worth $435,025

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . MYGN , a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium ® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries. Additional new data will show how Myriad's second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. "We are very excited to share validation data of our MRD assay. SABCS gives us the opportunity to showcase our clinical expertise in the prevention and treatment of early and advanced breast cancer," said George Daneker, MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. "Myriad is one of the only labs that can offer germline and tumor genomic testing, combined with customizable workflow solutions and point-of-care patient education sessions. Our test results are supported by treatment-focused reporting, concordance checks between germline and tumor genomic results, and a summary sheet designed to help oncologists and breast surgeons interpret actionable insights more effectively." Myriad Genetics Data Presentations Spotlight Presentation: Session 16, PS16-01: Polygenic Risk Date: Thursday, Dec. 12, 2024, 5:30-7:00 pm (CST), Hemisfair Ballroom 3 Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics The presentation will share longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors. Rapid-Fire Presentation: RF1-06 Date: Wednesday, Dec. 11, 2024, 12:00-12:50 pm (CST), Hall 1 Presenter: Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics Dr. Johansen Taber will share data detailing the association of polygenic-based breast cancer risk prediction with patient management. Poster Presentation: P2-04-23 Date: Wednesday, Dec. 11, 2024, 5:30-7:00 pm (CST), Halls 2-3 Presenter: Ashley Acevedo, PhD, Staff Computational Scientist, Myriad Genetics This poster shares the analytical validation of a high-definition tumor-informed Molecular Residual Disease (MRD) assay to demonstrate robust detection at low-tumor fractions, which are common in breast cancer. Poster Presentation: P3-02-10 Date: Thursday, Dec. 12, 2024, 12:30-2:00 pm (CST), Halls 2-3 Presenter: Holly Pederson, MD, Cleveland Clinic Dr. Pederson will share her evaluation of a polygenic risk score as a predictor of breast cancer, triple-negative breast cancer, and early-onset disease in Hispanic women. In addition to data presentations, Myriad will welcome attendees to its booth (#1327) during exhibition hours. Among the Myriad products highlighted in the company's SABCS exhibit are: MyRisk ® Hereditary Cancer Test evaluates 48 genes to help healthcare providers identify their patients' risk of developing 11 different types of hereditary cancer. MyRisk's clear, actionable results are the foundation for personalized care plans to help patients make confident, informed decisions about medical management. MyRisk with RiskScore ® provides unaffected patients with a comprehensive, personalized assessment of the five-year risk and remaining lifetime risk of developing breast cancer. Precise Tumor ® Molecular Profile Test is a pan-cancer solid tumor comprehensive genomic profiling test that helps clinicians with straightforward interpretations, prioritization of therapies, and the next steps specific to each patient's genomic result. MyChoice ® CDx is one of the most comprehensive homologous recombination deficiency (HRD) tests available, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). EndoPredict ® Breast Cancer Prognostic Test is for patients with ER+ , HER2- , node negative or node positive breast cancer. The test provides three individualized results used to help determine the most appropriate breast cancer treatment. About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com . Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company will present new data at SABCS and that the company's new data that will be shared at SABCS will show how the company's second-generation tumor-informed MRD assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Annual holiday light bike ride in Campbell River happening Dec. 7

49 ‘mystery drone’ sightings in one night, but not all were legit, N.J. governor says

Ravens' running game was crucial in a big win over the Chargers, especially on 4th down

Capitolis, the technology company helping to create safer and more vibrant capital markets, announced new strategic investments from four leading global banks. The new round is led by Citi and includes State Street, both existing investors in Capitolis, as well as new investors Morgan Stanley, and UBS. Each bank will invest $5 million and will join other existing investors including Andreessen Horowitz (a16z), Index Ventures, Sequoia Capital, S Capital, Spark Capital, SVB Capital, Canapi Ventures, 9Yards Capital, Standard Chartered and J.P. Morgan. The transaction and the funds it will generate will be used to fuel Capitolis’ growth across both its Capital Marketplace and Portfolio Optimization businesses. With an experienced and passionate team of global financial and technology executives, and some of the most innovative solutions in the industry, Capitolis has become a strategic partner to the financial industry. Its unique approach to working side-by-side with its customers to understand their core optimization issues and help solve for them is seen as a true differentiator. The need for the products Capitolis offers is expanding and as a result the company is seeing strong business momentum in terms of revenue growth, network participation and new product releases. Capitolis has been named as one of CNBC’s World’s Top Fintech Companies, World’s Best FX Software Provider in the Euromoney Foreign Exchange Awards, and one of Fast Company’s World’s Most Innovative Companies. “Capitolis has been partnering closely with the industry to make the financial markets safer and stronger within a well-regulated system, and we have seen tremendous growth because of this,” said Gil Mandelzis, CEO and Founder of Capitolis. “Our partnership with the world’s leading banks over the last few years has been terrific and we are excited to expand these relationships as well as add more of the world’s foremost financial institutions as both investors and board members.” “State Street is excited to continue our long-standing partnership with Capitolis. Welcoming additional key bank investors will further accelerate Capitolis’ success in capital markets optimization products,” said Tobias Krause, senior managing director, Risk and Capital Optimization at State Street.

Minerals Technologies Announces Successful Debt Refinancing

Port Moody approves provisional 5.71 percent property tax increase

Is the NORAD Santa tracker safe from a government shutdown?NVIDIA Announces Upcoming Events for Financial Community

Phreesia Announces Third Quarter Fiscal 2025 ResultsEl presidente electo de Estados Unidos, Donald Trump, sube al escenario para pronunciar un discurso en los FOX Nation Patriot Awards, el 5 de diciembre de 2024, en Greenvale, Nueva York. (AP Foto/Heather Khalifa) FILE – Robert F. Kennedy, Jr., speaks before Republican presidential nominee former President Donald Trump at a campaign event, Sept. 27, 2024 in Walker, Mich. (AP Photo/Carlos Osorio) FILE – Former Florida Attorney General Pam Bondi, speaks before Republican presidential nominee former President Donald Trump at a campaign rally at First Horizon Coliseum, Nov. 2, 2024, in Greensboro, NC. (AP Photo/Alex Brandon, File) FILE – Mehmet Oz visits the AW Driving School & License Testing Center in Allentown, Pa., Sept. 23, 2022. (AP Photo/Matt Rourke, File) FILE – Former Rep. Doug Collins speaks before Republican presidential nominee former President Donald Trump at a campaign event at the Cobb Energy Performing Arts Centre, Oct. 15, 2024, in Atlanta. (AP Photo/John Bazemore, File) El presidente electo de Estados Unidos, Donald Trump, sube al escenario para pronunciar un discurso en los FOX Nation Patriot Awards, el 5 de diciembre de 2024, en Greenvale, Nueva York. (AP Foto/Heather Khalifa) By CHRISTINE FERNANDO CHICAGO (AP) — As Donald Trump’s Cabinet begins to take shape, those on both sides of the abortion debate are watching closely for clues about how his picks might affect reproductive rights policy in the president-elect’s second term . Trump’s cabinet picks offer a preview of how his administration could handle abortion after he repeatedly flip-flopped on the issue on the campaign trail. He attempted to distance himself from anti-abortion allies by deferring to states on abortion policy, even while boasting about nominating three Supreme Court justices who helped strike down the constitutional protections for abortion that had stood for half a century. In an NBC News interview that aired Sunday, Trump said he doesn’t plan to restrict medication abortion but also seemed to leave the door open, saying “things change.” “Things do change, but I don’t think it’s going to change at all,” he said. The early lineup of his new administration , including nominations to lead health agencies, the Justice Department and event the Department of Veterans Affairs, has garnered mixed — but generally positive — reactions from anti-abortion groups. Abortion law experts said Trump’s decision to include fewer candidates with deep ties to the anti-abortion movement could indicate that abortion will not be a priority for Trump’s administration. “It almost seems to suggest that President Trump might be focusing his administration in other directions,” said Greer Donley, an associate law professor at the University of Pittsburgh School of Law. Karen Stone, vice president of public policy at Planned Parenthood Action Fund , said while many of the nominees have “extensive records against reproductive health care,” some do not. She cautioned against making assumptions based on Trump’s initial cabinet selections. Still, many abortion rights groups are wary, in part because many of the nominees hold strong anti-abortion views even if they do not have direct ties to anti-abortion activists. They’re concerned that an administration filled with top-level officials who are personally opposed to abortion could take steps to restrict access to the procedure and funding. After Trump’s ambiguity about abortion during his campaign, “there’s still a lot we don’t know about what policy is going to look like,” said Mary Ruth Ziegler, a law professor at the University of California, Davis School of Law. That approach may be revealed as the staffs within key departments are announced. Trump announced he would nominate anti-vaccine activist Robert F. Kennedy Jr. to lead the Health and Human Services Department, which anti-abortion forces have long targeted as central to curtailing abortion rights nationwide. Yet Kennedy shifted on the issue during his own presidential campaign. In campaign videos, Kennedy said he supports abortion access until viability , which doctors say is sometime after 21 weeks, although there is no defined timeframe. But he also said “every abortion is a tragedy” and argued for a national ban after 15 weeks of pregnancy, a stance he quickly walked back. The head of Health and Human Services oversees Title X funding for a host of family planning services and has sweeping authority over agencies that directly affect abortion access, including the Food and Drug Administration and Centers for Medicare and Medicaid Services. The role is especially vital amid legal battles over a federal law known as EMTALA, which President Joe Biden’s administration has argued requires emergency abortion access nationwide, and FDA approval of the abortion pill mifepristone. Mini Timmaraju, president of the national abortion rights organization Reproductive Freedom for All, called Kennedy an “unfit, unqualified extremist who cannot be trusted to protect the health, safety and reproductive freedom of American families.” His potential nomination also has caused waves in the anti-abortion movement. Former Vice President Mike Pence , a staunch abortion opponent, urged the Senate to reject Kennedy’s nomination. Marjorie Dannenfelser, president of the national anti-abortion group Susan B. Anthony Pro-Life America, said the group had its own concerns about Kennedy. “There’s no question that we need a pro-life HHS secretary,” she said. Fox News correspondent Marty Makary is Trump’s pick to lead the FDA, which plays a critical role in access to medication abortion and contraception. Abortion rights groups have accused him of sharing misinformation about abortion on air. Russell Vought , a staunch anti-abortion conservative, has been nominated for director of the Office of Management and Budget. Vought was a key architect of Project 2025 , a right-wing blueprint for running the federal government. Among other actions to limit reproductive rights, it calls for eliminating access to medication abortion nationwide, cutting Medicaid funding for abortion and restricting access to contraceptive care, especially long-acting reversible contraceptives such as IUD’s. Despite distancing himself from the conservative manifesto on the campaign trail, Trump is stocking his administration with people who played central roles in developing Project 2025. Trump acknowledged that drafters of the report would be part of his incoming administration during the Sunday interview with NBC News, saying “Many of those things I happen to agree with.” “These cabinet appointments all confirm that Project 2025 was in fact the blueprint all along, and the alarm we saw about it was warranted,” said Amy Williams Navarro, director of government relations for Reproductive Freedom for All. Dr. Mehmet Oz , Trump’s choice to lead the Centers for Medicare and Medicaid Services, is a former television talk show host who has been accused of hawking dubious medical treatments and products. He voiced contradictory abortion views during his failed Senate run in 2022. Oz has described himself as “strongly pro-life, praised the Supreme Court decision overturning Roe v. Wade , claimed “life starts at conception” and referred to abortion as “murder.” But he also has echoed Trump’s states-rights approach, arguing the federal government should not be involved in abortion decisions. “I want women, doctors, local political leaders, letting the democracy that’s always allowed our nation to thrive to put the best ideas forward so states can decide for themselves,” he said during a Senate debate two years ago. An array of reproductive rights groups opposed his Senate run. As CMS administrator, Oz would be in a key position to determine Medicaid coverage for family planning services and investigate potential EMTALA violations. Related Articles National Politics | In promising to shake up Washington, Trump is in a class of his own National Politics | Election Day has long passed. In some states, legislatures are working to undermine the results National Politics | Trump taps his attorney Alina Habba to serve as counselor to the president National Politics | With Trump on the way, advocates look to states to pick up medical debt fight National Politics | Ballot recount confirms Woog’s win in House District 19 As Florida’s attorney general, Pam Bondi defended abortion restrictions, including a 24-hour waiting period. Now she’s Trump’s choice for attorney general . Her nomination is being celebrated by abortion opponents but denounced by abortion rights groups concerned she may revive the Comstock Act , an anti-vice law passed by Congress in 1873 that, among other things, bans mailing of medication or instruments used in abortion. An anti-abortion and anti-vaccine former Florida congressman, David Weldon, has been chosen to lead the Centers for Disease Control and Prevention, which collects and monitors abortion data across the country. Former Republican congressman Doug Collins is Trump’s choice to lead the Department of Veterans Affairs amid a political battle over abortion access and funding for troops and veterans. Collins voted consistently to restrict funding and access to abortion and celebrated the overturning of Roe v. Wade. “This is a team that the pro-life movement can work with,” said Kristin Hawkins, president of the national anti-abortion organization Students for Life.

Related hot word search:

Previous: online casino slot games real money
Next: lucky casino slot